Company / Accounts Receivable
Biogen Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.3B
FY2025
5-year range
$1.3B / $1.7B
FY2021-FY2025
Trend
-4.4%
vs FY2024
Sector context
#14 of 115
Health Care
What the data says
Biogen's accounts receivable of $1.3B is higher than 88% of companies in the Health Care sector (FY2025). Accounts Receivable has declined for 3 consecutive years, from $1.7B in FY2022 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of -6.8%. Top quartile in the Health Care sector.
Declined from $1.7B to $1.3B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -7.7%
- 5-Year CAGR
- -6.8%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 115This company $1.3B Sector average $1.1B
▼
+19.9% above sector average
Key checks
Key Insights
- Biogen's accounts receivable has declined for 3 consecutive years.
- 5-year CAGR of -6.8%, indicating a declining trend.
- In FY2025, accounts receivable decreased 4.4% year-over-year.
- Ranks #14 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | -4.4% |
| FY2024 | $1.4B | -15.6% |
| FY2023 | $1.7B | -2.4% |
| FY2022 | $1.7B | +10.0% |
| FY2021 | $1.5B | -19.0% |
| FY2020 | $1.9B | +1.8% |
| FY2019 | $1.9B | -4.0% |
| FY2018 | $2.0B | +9.6% |
| FY2017 | $1.8B | +24.0% |
| FY2016 | $1.4B | +17.5% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026